Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bioventus (BVS) EPS (Weighted Average and Diluted) (2021 - 2026)

Bioventus filings provide 5 years of EPS (Weighted Average and Diluted) readings, the most recent being $0.21 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) changed N/A to $0.21 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.33, a 158.93% increase, with the full-year FY2025 number at $0.33, up 158.93% from a year prior.
  • EPS (Weighted Average and Diluted) hit $0.21 in Q4 2025 for Bioventus, up from $0.05 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.86 in Q4 2023 to a low of -$1.76 in Q4 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.08 (2024), compared with a mean of -$0.18.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 5766.67% in 2022 and later soared 265.38% in 2023.
  • Bioventus' EPS (Weighted Average and Diluted) stood at $0.04 in 2021, then plummeted by 1400.0% to -$0.52 in 2022, then soared by 265.38% to $0.86 in 2023, then plummeted by 109.3% to -$0.08 in 2024, then soared by 362.5% to $0.21 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.21 (Q4 2025), $0.05 (Q3 2025), and $0.11 (Q2 2025) per Business Quant data.